|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:approvedBy
|
gptkb:FDA
1991
|
|
gptkbp:ATCCode
|
gptkb:N06AB06
|
|
gptkbp:availableOn
|
gptkb:tablet
oral solution
|
|
gptkbp:blackBoxWarning
|
increased risk of suicidal thinking and behavior in children, adolescents, and young adults
|
|
gptkbp:brand
|
gptkb:Lustral
gptkb:Zoloft
|
|
gptkbp:CASNumber
|
gptkb:79617-96-2
|
|
gptkbp:chemicalFormula
|
C17H17Cl2N
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:drugClass
|
selective serotonin reuptake inhibitor
|
|
gptkbp:eliminationHalfLife
|
26 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericName
|
gptkb:sertraline
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zoloft
|
|
gptkbp:indication
|
gptkb:obsessive-compulsive_disorder
gptkb:panic_disorder
gptkb:post-traumatic_stress_disorder
gptkb:social_anxiety_disorder
gptkb:major_depressive_disorder
premenstrual dysphoric disorder
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:MAO_inhibitors
gptkb:NSAIDs
gptkb:pimozide
other serotonergic drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2006
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children (OCD only)
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
suicidal thoughts (in young people)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
dizziness
insomnia
dry mouth
sexual dysfunction
|
|
gptkbp:bfsParent
|
gptkb:Pfizer
|
|
gptkbp:bfsLayer
|
4
|